Brought to you by 
CANbridge brings in $25mm through Series B round
23 May 2017
Executive Summary
CANbridge Life Sciences Ltd. (developing oncology drugs, diagnostics, and devices for the Chinese and Northern Asian markets) raised $25mm through its Series B round to Lapam Capital (lead), Qiming Venture Partners, Yuanming Capital, Yanyuang Capital, Biossom Investment Management, and Wuxi AppTec. Money will support development of immunotherapy candidates CAN008 (Phase I/II for glioblastoma multiforme) and CAN017 (completed Phase I) for esophageal squamous cell cancer.
Deal Industry
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CANbridge brings in $25mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice